Comparision of Effects of Rosuvastatin Versus Atorvastatin Treatment on Plasma Levels of Asymmetric Dimethylarginine in Patients With Hyperlipidemia Having Coronary Artery Disease
Restricted accessResearch articleFirst published online October, 2014
Comparision of Effects of Rosuvastatin Versus Atorvastatin Treatment on Plasma Levels of Asymmetric Dimethylarginine in Patients With Hyperlipidemia Having Coronary Artery Disease
Elevated plasma levels of asymmetric dimethylarginine (ADMA) are prevalent in patients with hypercholesterolemia and coronary artery disease. A total of 83 patients with hypercholesterolemia and angiographically documented mild coronary artery stenosis were randomized to rosuvastatin treatment (20 mg) or atorvastatin treatment (40 mg) once daily for 6 weeks after a 4-week dietary lead-in phase. Both statins decreased total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and triglyceride levels effectively. Only rosuvastatin increased high-density lipoprotein cholesterol (HDL-C) levels. Both rosuvastatin and atorvastatin decreased plasma ADMA levels; rosuvastatin had a significantly greater effect. The reduction in ADMA levels were correlated with the reduction in TC and LDL-C levels as well as LDL-C–HDL-C ratio. Treatment with rosuvastatin or atorvastatin in patients with hyperlipidemia with mild coronary artery stenosis may lead to a decrease in ADMA levels, which may contribute to improved endothelial function.
BaigentCKeechAKearneyPM; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267–1278.
2.
MihosCGSalasMJSantanaO. The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review. Cardiol Rev. 2010;18(6):298–304.
3.
StroesESKoomansHAde BruinTWRabelinkTJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet. 1995;346(8973):467–471.
4.
Vladimirova-KitovaLGDeneva-KoychevaTI. The effect of simvastatin on asymmetric dimethylarginine and flow-mediated vasodilation after optimizing the LDL level: a randomized, placebo-controlled study. Vascul Pharmacol. 2012;56(3-4):122–130.
5.
EidHMEritslandJLarsenJArnesenHSeljeflotI. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. effects of pravastatin. Atherosclerosis. 2003;166(2):279–284.
6.
LuTMDingYALeuHBYinWHSheuWHChuKM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol. 2004;94(2):157–161.
7.
LeiperJVallanceP. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res. 1999;43(3):542–548.
8.
JiangJJiangDTangYLiNDengHLiY. Effect of simvastatin on endothelium-dependent vaso-relaxation and endogenous nitric oxide synthase inhibitor. Acta Pharmacol Sin. 2004;25(7):893–901.
9.
SchulzeFLenzenHHanefeldC, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter coronary artery risk determination investigating the influence of ADMA concentration (CARDIAC) study. Am Heart J. 2006;152(3):493.e1–e8.
10.
BögerRHVallancePCookeJP. Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atherosclerosis. 2003;4(4):1–3.
11.
BögerRH. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann Med. 2006;38(2):126–136.
12.
MiyazakiHMatsuokaHCookeJP. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99(9):1141–1146.
13.
AkyelAÇengelATavilY. Relationship between plasma asymmetric dimethylarginine level and autonomic dysfunction in diabetic patients. Turk Kardiyol Dern Ars. 2012;40(2):148–154.
14.
PäiväHLaaksoJLehtimäkiTIsomustajärviMRuokonenILaaksonenR. Effectof high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors. J Cardiovasc Pharmacol. 2003;41(2):219–222.
15.
BolayirlıIMAslanMBalciHAltugTHacibekirogluMSevenA. Effects of atorvastatin therapy on hypercholesterolemic rabbits with respect to oxidative stress, nitric oxide pathway and homocysteine. Life Sci. 2007;81(2):121–127.
16.
ValkonenVPLaaksoJPäiväH. Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels?Atheroscler Suppl. 2003;4(4):19–22.
17.
YoungJMStreyCHGeorgePM. Effect of atorvastatinon plasma levels of asymmetric dimethylarginine in patients with non-ischaemic heart failure. Eur J Heart Fail. 2008;10(5):463–466.
18.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143–421.
19.
FriedewaldWTLevyRIFredericksonDS. Estimation of concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499–502.
20.
SiasosGTousoulisDAntoniadesCStefanadiE, Stefanadis C. l-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis?Int J Cardiol. 2007;116(3):300–308.
21.
BögerRHBode-BögerSMSzubaA. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98(18):1842–1847.
22.
SurdackiANowickiMSandmannJ. Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetrical dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol. 1999;33(4):652–658.
23.
KielsteinJTBögerRHBode-BögerSM. Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol. 1999;10(3):594–600.
24.
GorenfloMZhengCWerleEFiehnWUlmerHE. Plasma levels of asymmetrical dimethyl-l-arginine in patients with congenital heart disease and pulmonary hypertension. J Cardiovasc Pharmacol. 2001;37(4):489–492.
25.
ValkonenVPPäiväHSalonenJT. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358(9299):2127–2128.
26.
MeinitzerASeelhorstUWellnitzB. Asymmetrical dimethylarginine independently predicts total cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen risk and cardiovascular health study). Clin Chem. 2007;53(2):273–283.
27.
DückelmannCMittermayerFHaiderDGAltenbergerJEichingerJWolztM. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol. 2007;27(9):2037–2042.
28.
ZoccaliCBode-BögerSMMallamaciF. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet. 2001;358(9299):2113–2117.
29.
ItoATsaoPSAdimoolamSKimotoMOgawaTCookeJP. Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation. 1999;99(24):3092–3095.
30.
BögerRHSydowKBorlakJ. LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res. 2000;87(2):99–105.
31.
CookeJP. Does ADMA cause endothelial dysfunction?Arteriosclerosis Thrombosis Vascular Biol. 2000;20(9):2032–2037.
32.
LorinJGuillandJCKorandjiC. High levels of asymmetric dimethylarginine are strongly associated with low HDL in patients with acute myocardial infarction. PLoS ONE. 2013;8(6):e64796.
33.
BiXYHeXZhaoMYuXJZangWJ. Role of endothelial nitric oxide synthase and vagal activity in the endothelial protection of atorvastatin in ischemia/reperfusion injury. J Cardiovasc Pharmacol. 2013;61(5):391–400.
34.
HeebaGHassanMKKhalifaMMalinskiT. Adverse balance of nitric oxide/peroxynitrite in the dysfunctional endothelium can be reversed by statins. J Cardiovasc Pharmacol. 2007;50(4):391–398.
NichollsSJBrandrup-WognsenGPalmerMBarterPJ. Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER). Am J Cardiol. 2010;105(1):69–76.
37.
JonesPHDavidsonMHSteinEA; STELLAR Study Group. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92(2):152–160.
38.
SchusterHBarterPJStenderS; Effective reductions in cholesterol using rosuvastatin therapy I study group. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J. 2004;147(4):705–713.
39.
TsiaraSElisafMMikhailidisDP. Early vascular benefits of statin therapy. Curr Med Res Opin. 2003;19(6):540–556.
40.
TziomalosKAthyrosVGKaragiannisAMikhailidisDP. Lipid lowering agents and the endothelium: an update after 4 years. Curr Vasc Pharmacol. 2012;10(1):33–41.
